AEON Biopharma, Inc. (AEON:NYSEMKT) closed at $0.239 on October 22, 2026, down 0.54% on the day. The stock trades 83.5% below its 52-week high of $1.45 and 35.0% above its 52-week low of $0.177. Over the past year, it lost 76.5%. AEON Biopharma, Inc. is part of the Health Care sector.
In 252 trading sessions since October 21, 2025, AEON closed higher on 106 days (42%). Its best day was September 10, 2026 (+25.54%) and its worst was July 13, 2026 (-33.33%). The stock moved 10% or more in a single session 26 times. It opened at least 5% above the previous day's high 4 times.
AEON Biopharma, Inc. is a bio-pharmaceutical company. The Company is focused on developing ABP-450 (prabotulinumtoxinA) injection for the treatment of debilitating medical conditions with an initial focus on the neurology and gastroenterology markets. ABP-450 contains a 900 kDa botulinum toxin type-A complex produced by the bacterium clostridium botulinum. The active part of the botulinum toxin is the 150 kDa component, and the remaining 750 kDa of the complex is made up of accessory proteins. When injected at therapeutic levels, ABP-450 blocks peripheral acetylcholine release at presynaptic cholinergic nerve terminals by cleaving SNAP-25, a protein integral to the docking and release of acetylcholine from vesicles situated within the nerve endings leading to denervation and relaxation of the muscle. It is also engaged in the Phase II clinical study of ABP-450 for the treatment of cervical dystonia. Cervical dystonia, also known as spasmodic torticollis, is a neurological condition.
Find more stocks like AEON with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.